Pseudosciaena crocea antimicrobial peptide LcPLA2XIIA as well as preparation method and application thereof
Through the development and recombinant expression of the antimicrobial peptide LcPLA2XIIA of the big yellow croaker, the problems of drug resistance of pathogenic bacteria of visceral white spot disease and insufficient activity of Candida albicans in the big yellow croaker breeding were solved, and effective inhibition and resistance of various pathogenic microorganisms were achieved. Viral effects provide new antipathogenic drugs and additives solutions for aquaculture.
Patent Information
- Application Number
- CN202411094960.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-11
- Publication Date
- 2024-11-19
AI Technical Summary
In the breeding of yellow croaker, bacteria are seriously resistant to pathogenic bacteria, existing antibiotics are difficult to effectively prevent and treat, and the activity of Candida albicans against antibacterial peptides is rarely reported, which leads to challenges in the prevention and control of aquatic diseases.
The antimicrobial peptide of the big yellow croaker, LcPLA2XIIA, was developed by designing primers, PCR amplification, and constructing the recombinant expression vector pET32a/LcPLA2XIIA, and purifying the expression in E. coli Rosetta (DE3) to obtain the peptide. It was used to prepare antibacterial, antifungal and antiviral Drugs or additives.
LcPLA2XIIA showed significant antibacterial, antifungal and antiviral activities, especially the infectious hematopoietic organ necrosis virus IHNV, and has inhibitory effects on drug-resistant bacteria such as Candida albicans, providing new antipathogens. Microbial infection control and application prospects of feed additives.
Smart Images

Figure CN118978581A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to a large yellow croaker antimicrobial peptide LcPLA2XIIA and a preparation method and application thereof. Background Art
[0002] Large yellow croaker is an important marine aquaculture fish in my country. While the large yellow croaker aquaculture industry is developing rapidly, it is also facing problems such as frequent outbreaks of diseases and degradation of germplasm resources, among which the disease problem of large yellow croaker is particularly prominent. The main epidemics of large yellow croaker include Cryptocaryon irritans, visceral white spot disease and iridovirus disease, while visceral white spot disease of large yellow croaker is the most serious bacterial disease. The outbreak of this disease has caused huge economic losses to the large yellow croaker aquaculture industry. Due to the early use of antibiotics to prevent and control the disease, the pathogen has now developed serious drug resistance, and the pathogen also has the characteristics of facultative intracellular parasitism, making the prevention and treatment of visceral white spot disease more difficult.
[0003] As crucial effector molecules in the host's innate immune system, antimicrobial peptides play an important role in defending against bacterial, viral, fungal and parasitic infections. Some members of the PLA2 superfamily, such as human PLA2II and PLA2XII, exhibit significant antimicrobial activity and are considered to be new members of the antimicrobial peptide family. In addition, some members of the PLA2 superfamily exhibit antiviral capabilities in different ways, such as PLA2s from snake venom and bee venom, which exhibit antiviral activity against human immunodeficiency virus (HIV) by interacting with host cells and blocking viral entry into cells. Given the multifunctional properties of PLA2s, in recent years, it has been found that some fish PLA2s respond to bacterial stimulation or exhibit strong antibacterial activity, participating in the host's antimicrobial immune response.
[0004] Although current studies have shown that PLA2 family proteins have a relatively broad spectrum of antimicrobial activity, there are few reports on the activity of such proteins against Candida albicans, which is a pathogen of higher animals including humans. The protein can be obtained through certain channels and used as a new antifungal drug. IHNV is the main pathogen of cold-water fish rainbow trout and Atlantic salmon. Given that bacterial resistance is very common in aquaculture, the use of conventional antibiotics and other drugs often does not achieve the expected results. Therefore, the development of new anti-resistant bacteria drugs is also an important topic in the prevention and control of aquatic diseases. Summary of the invention
[0005] The present invention is to solve the above problems and provides a large yellow croaker antimicrobial peptide LcPLA2XIIA and a preparation method and application thereof.
[0006] The present invention adopts the following technical scheme: a large yellow croaker antimicrobial peptide LcPLA2XIIA, the amino acid sequence of which is shown in SEQID NO.1.
[0007] The coding gene of the large yellow croaker antimicrobial peptide LcPLA2XIIA, the nucleotide sequence of which is shown in SEQ ID NO.2.
[0008] A method for preparing a large yellow croaker antimicrobial peptide LcPLA2XIIA comprises the following steps:
[0009] (1) According to the mature peptide encoded by the ORF sequence of the antimicrobial peptide LcPLA2XIIA gene, primers were designed and the nucleic acid sequence corresponding to the mature peptide of LcPLA2XIIA was amplified by PCR, wherein the amino acid sequence of the mature peptide of the antimicrobial peptide LcPLA2XIIA is positions 19-186 of the amino acid sequence shown in SEQ ID NO.1;
[0010] (2) Construction of recombinant expression vector pET32a / LcPLA2XIIA;
[0011] (3) The recombinant expression vector in step (2) was transformed into host cells Rosetta DE3, the host cells were induced to express, and the antimicrobial peptide LcPLA2XIIA was obtained by affinity chromatography purification.
[0012] Furthermore, in the step (1), primer LcPLA2XIIAEF and primer LcPLA2XIIAER are paired, the nucleotide sequence of primer LcPLA2XIIAEF is shown in SEQ ID NO.5, the nucleotide sequence of primer LcPLA2XIIAER is shown in SEQ ID NO.6, and the cDNA of LcPLA2XIIA is used as a template.
[0013] Application of the antimicrobial peptide LcPLA2XIIA in the preparation of antibacterial drugs, antifungal drugs or antiviral drugs.
[0014] Furthermore, the fungus includes Candida albicans.
[0015] Furthermore, the pathogenic bacteria include Pseudomonas auriculatus, Aeromonas hydrophila, Vibrio parahaemolyticus, Escherichia coli or Staphylococcus aureus.
[0016] Furthermore, the virus is infectious hematopoietic necrosis virus IHNV.
[0017] Application of antimicrobial peptide LcPLA2XIIA in the preparation of animal anti-pathogenic microbial feed additives.
[0018] The advantages of the present invention are specifically as follows:
[0019] (1) The present invention successfully recombined and expressed the mature peptide protein of the antimicrobial peptide LcPLA2XIIA gene in Escherichia coli Rosetta (DE3) through the sequence recombinant expression vector pET32a / LcPLA2XIIA encoding the mature peptide. The antimicrobial peptide LcPLA2XIIA has good antibacterial, antifungal and antiviral activities, especially obvious antiviral activity against infectious hematopoietic necrosis virus IHNV, which lays a good foundation for its development as a new drug or new feed additive.
[0020] (2) LcPLA2XIIA is a rare antifungal antimicrobial peptide. The antimicrobial peptide LcPLA2XIIA has a strong anti-Candida albicans function. Compared with other antimicrobial peptides, the antimicrobial peptide LcPLA2XIIA obtained by the present invention has obvious inhibitory activity and killing effect on three common aquatic drug-resistant bacteria: Aeromonas hydrophila, Vibrio parahaemolyticus, and Pseudomonas aeruginosa. Therefore, it has broad application prospects in the development and application of new antimicrobial infection drugs and new anti-disease feed additives, and can be used for the control of aquatic drug-resistant bacteria. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The electrophoresis patterns of proteins before and after induction and purified LcPLA2XIIA in the pET32a / LcPLA2XIIA recombinant expression system of the present invention are shown.
[0022] Among them: 1 is the expression of Escherichia coli Rosetta (DE3) protein before induction; 2 is the expression of Escherichia coli Rosetta (DE3) protein after induction; 3 is the purified LcPLA2XIIA protein sample; M is the protein marker.
[0023] Figure 2 These are the experimental results of the binding between the antimicrobial peptide LcPLA2XIIA of the present invention and the bacterial polysaccharide component LTA.
[0024] Figure 3 This is a graph showing the effect of the antimicrobial peptide LcPLA2XIIA of the present invention on the proliferation trend of the virus IHNV. DETAILED DESCRIPTION
[0025] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and understandable, the present invention is further explained and illustrated below in conjunction with specific drawings and embodiments.
[0026] Example 1: Extraction of total RNA from hepatopancreas of large yellow croaker and synthesis of cDNA:
[0027] The steps for extracting total RNA from hepatopancreas are as follows: add fresh hepatopancreas tissue sample at a volume of 50 mg tissue / mL Trizol reagent, and homogenize in an ice bath; transfer the homogenate into a sterile 1.5 mL centrifuge tube, centrifuge at 4°C, 12,000 rpm for 10 min to remove the precipitate, transfer the supernatant into a new 1.5 mL centrifuge tube, and let stand at room temperature at 15-30°C for 5 min to fully lyse the nucleoprotein complex; add 0.2 mL chloroform at a volume of 0.2 mL chloroform / mL Trizol reagent, shake vigorously for 15 s, let stand at room temperature at 15-30°C for 2-3 min, and centrifuge at 12,000 rpm for 15 min at low temperature; transfer the upper aqueous phase to a new 1.5 mL centrifuge tube, add 0.5 mL isopropanol at a volume of 0.5 mL isopropanol / mL Trizol reagent, mix the solution thoroughly and slowly, let stand at room temperature at 15-30°C for 10 min to precipitate RNA; centrifuge at 12,000 rpm for 10 min at low temperature, remove the supernatant, and press 1 mL 70% ethanol / mL Wash the RNA precipitate with Trizol reagent, vortex briefly for a few seconds on a vortex shaker, and centrifuge at 7,500 rpm for 5 minutes at 4°C; finally, remove the supernatant, air-dry the RNA precipitate at room temperature, add DEPC-treated water to dissolve the RNA precipitate, incubate at 55-60°C for 10 minutes, and store at -80°C after aliquoting.
[0028] The method for removing DNA contamination is as follows: add the above RNA to an RNase-free EP tube in sequence, add DNase I (1U / μl) at 1U / μg RNA, and incubate at 37°C for 30 minutes; then add 1μl 25mM EDTA and incubate at 65°C for 10 minutes to inactivate DNase I.
[0029] The cDNA synthesis process is as follows: add 4 μL total RNA (1-5 μg) and 1L primer Oligo-T (18) (100 μM) (SEQ ID NO. 7) to an RNase-free centrifuge tube, gently mix, and centrifuge briefly; incubate in a 70°C water bath for 5 minutes, and cool on ice for 2 minutes; centrifuge briefly to concentrate all components at the bottom of the tube, and continue to add the following reagents in Table 1 to the tube on ice for 30 seconds:
[0030] Table 1 Reagent dosage
[0031]
[0032]
[0033] The total volume of 25 μL of the reaction solution was gently mixed, centrifuged instantaneously, and placed in a 42°C water bath for 60 min. Finally, the reaction was terminated by placing in a 70°C water bath for 15 min, and cooled on ice.
[0034] Example 2: Obtaining the full-length nucleic acid sequence and amino acid sequence of the open reading frame of the large yellow croaker antimicrobial peptide LcPLA2XIIA.
[0035] PCR amplification of the LcPLA2XIIA open reading frame DNA sequence: The cDNA template, the upstream primer SEQ ID NO.3, the downstream primer SEQ ID NO.4, and other components were mixed in proportion to form a PCR reaction system, as shown in Table 2 below:
[0036] Table 2 Reagent dosage
[0037]
[0038] The above reaction system was subjected to PCR cycling, and the PCR cycling conditions are shown in the table below: the reaction started at 94°C for 3 min; followed by 29 cycles of amplification of the target fragment, with reaction parameters of 94°C denaturation for 30 s, 53°C annealing for 30 s, and 72°C extension for 20 s; and finally, extension at 72°C for 10 min.
[0039] The PCR product after the above amplification was subjected to gel electrophoresis, and the amplification result was preliminarily determined based on the size of the electrophoresis band. The PCR product was then further sent to Shanghai Shenggong Biotechnology Co., Ltd. for sequencing to obtain the full-length open reading frame DNA sequence of the gene (SEQ ID NO.2). The full length of the LcPLA2XIIA open reading frame is 561 bp.
[0040] The LcPLA2XIIA protein sequence (SEQ ID NO. 1) contains 186 amino acids in total, of which the 19th to 186th amino acids are mature peptide sequences, and there is also an 18-amino acid signal peptide sequence at the front end of the mature peptide.
[0041] Example 3 Construction of LcPLA2XIIA prokaryotic expression vector
[0042] The DNA sequence corresponding to the mature peptide of LcPLA2XIIA was amplified with the upstream primer LcPLA2XIIAEF (SEQ ID NO.5) and the downstream primer LcPLA2XIIAER (SEQ ID NO.6). The PCR reaction conditions were: 95°C pre-denaturation for 3 min, 95°C denaturation for 30 s, 53°C annealing for 45 s, 72°C extension for 45 s, a total of 35 cycles, and finally 72°C extension for 5 min. The PCR products were analyzed by 1.5% agarose gel electrophoresis and the positive fragments were recovered.
[0043] The purified and recovered nucleic acid fragment and the expression vector pET32a were digested with endonucleases EcoR Ⅰ and Hind III, respectively. After digestion at 37°C for 3 h, 1 μL of the digestion product was subjected to 1% agarose gel electrophoresis to detect the digestion effect.
[0044] The target nucleic acid fragment and the vector after enzyme digestion were recovered and purified using a gel recovery kit, and the ligation reaction solution was prepared according to the conventional method, mixed and ligated at 16°C overnight. The above overnight ligation solution was transformed into E. coli DH5α competent cells, positive clones were screened, and sequencing was performed to ensure that the reading frame of the constructed recombinant expression vector was correct.
[0045] Example 4: Inducible expression of the recombinant expression vector in Escherichia coli Rosetta (DE3).
[0046] The constructed recombinant expression vector pET32a / LcPLA2XIIA was transformed into Escherichia coli Rosetta (DE3) competent cells; a small amount of screened positive clones were cultured, and IPTG with a final concentration of 0.1 mM was added to induce the expression of the target protein; the bacterial liquid before and after induction was collected, and protein samples were prepared respectively, and the expression of the target protein was detected by polyacrylamide gel electrophoresis (gel concentration 15%); the protein electrophoresis results are shown in FIG. Figure 1 shown.
[0047] Depend on Figure 1 It can be seen that compared with before induction, the E. coli containing the recombinant expression vector each showed an additional obvious protein band, which was consistent with the predicted theoretical molecular weight, indicating that the additional band was the recombinant protein LcPLA2XIIA.
[0048] Example 5: Purification of recombinant protein LcPLA2XIIA
[0049] According to the results of the trial expression experiment, the above two expression strains were selected for scale culture (culture medium volume 300 ml) at 28°C, and IPTG with a final concentration of 0.1mM was used to induce protein expression. The induced bacterial solution was centrifuged to remove the supernatant and resuspended in 1×PBS (140mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, pH7.4). After ultrasonic disruption in an ice bath, the supernatant and precipitate were separated by centrifugation at 12,000rpm for 20min (4°C). Protein expression was detected in the supernatant by electrophoresis, and LcPLA2XIIA was soluble. Finally, the collected supernatant was subjected to affinity chromatography (Ni-NTA His Bind Resin, QIAGEN, Germany), and the eluate was collected, dialyzed and concentrated to obtain the target protein: antimicrobial peptide LcPLA2XIIA.
[0050] Example 6: Antimicrobial peptide LcPLA2XIIA possesses significant antibacterial activity
[0051] The protein curve was prepared using BSA standard, and the concentration of LcPLA2XIIA protein was determined by Bradford method. The antibacterial activity of the recombinant protein was determined according to the minimum inhibitory concentration (MIC) method of liquid antibacterial sensitivity test. The specific operation was as follows: after the recombinant protein was sterilized by filtration, it was diluted in multiple ratios in 96-well plates (each well containing 100 μL protein sample) using 10 mM sodium phosphate buffer (pH 7.4); TRX (negative control) was also treated in the same way; then 100 μL containing approximately 1×10 5 The LB culture medium of CFU bacteria was added to the corresponding protein dilution solution and incubated at 37°C for 16 hours. The selected bacteria and fungi species include: Pseudomonas aeruginosa, Aeromonas hydrophila, Vibrio parahaemolyticus, Escherichia coli, Staphylococcus aureus, yeast and Candida albicans. Experimental and control groups: Blank control group: add 100μL phosphate buffer and 100μL LB culture medium; Negative control group: add 100μL phosphate buffer containing pET32a carrier protein (TRX) and 100μL LB culture medium; Experimental group: add 100μL phosphate buffer containing LcPLA2XIIA protein and 100μL LB culture medium;
[0052] MIC is defined here as the concentration (OD value) of the bacterial growth suspension under the highest dilution concentration condition with a significant visible change (significant difference) compared with the negative control group. See Table 3 for specific results.
[0053] Table 3 Effects on microorganisms
[0054]
[0055] As shown in Table 3, protein TRX had no inhibitory activity against the tested bacteria and fungi, but LcPLA2XIIA showed obvious inhibitory activity against Gram-positive bacteria, Gram-negative bacteria and Candida albicans. The smaller the MIC value, the stronger the ability to inhibit bacterial growth or kill bacteria.
[0056] Example 7: Binding activity experiment of lipoteichoic acid (LTA), a component of the cell wall of Gram-positive bacteria
[0057] The differences in binding activity of LcPLA2XIIA and TRX to bacterial sugar component LTA were compared by enzyme-linked immunosorbent assay (ELISA). The specific operation steps are as follows: first, add 100 μL of 20 μg / ml LTA solution to a 96-well plate and leave it at room temperature until it evaporates completely; add 200 μL of 1 mg / ml BSA to each well for blocking for 2 hours, then wash with TBS 4 times; dilute the protein in a certain proportion and add 100 μL to each well, incubate at room temperature for 3 hours; then wash with TBS 4 times; add 100 μL of diluted horseradish peroxidase-labeled specific antibody (1:5000) to each well and incubate at 37°C for 1-2 hours; after washing with TBS 4 times, add 100 μL of prepared TMB color development solution to each well, according to the experimental situation (about 5 minutes), add 50 μL of 2M H2SO4 to terminate the reaction, and measure the OD value at a wavelength of 405 nm. The carrier protein TRX was used as the experimental control group. Draw according to the experimental results Figure 2 .
[0058] Depend on Figure 2 It can be seen that compared with TRX, the recombinant protein LcPLA2XIIA has a stronger binding ability with the bacterial polysaccharide component LTA, indicating that the enhancement of antibacterial activity is related to the binding with bacterial polysaccharides. The results of this example further explain the results of Example 6.
[0059] Example 8: LcPLA2XIIA has significant antiviral activity
[0060] EPC cells were cultured in DMEM medium containing 10% fetal bovine serum, and the incubator temperature was set at 25°C and the CO2 concentration was set to 5%. The Reed and Muench method was used to detect the 50% tissue culture cell infection dose (TCID50) of IHNV. IHNV (100TCID50) was pre-incubated with recombinant protein LcPLA2XIIA (2.0μM) or TRX in DMEM containing 5% FBS for 2h. After the cells were cultured to 70%-80% confluence, the mixture was transferred to the plate wells and washed 3 times with PBS. After incubation for 2h, DMEM containing 5% FBS was added to the wells. Cells and culture medium were collected at 12, 24, 36 and 48h after infection, and the proliferation pattern of IHNV was analyzed. The virus copy number was calculated using a virus quantitative detection method developed in the laboratory.
[0061] like Figure 3 As shown, pre-incubation of IHNV with the antimicrobial peptide LcPLA2XIIA can significantly inhibit the proliferation of IHNV in EPC cells. At 24, 36 and 48 h after infection, the number of IHNV pre-incubated with the antimicrobial peptide LcPLA2XIIA was significantly less than that of IHNV pre-incubated with TRX or untreated (blank control), indicating that the antimicrobial peptide LcPLA2XIIA has antiviral activity against IHNV.
Claims
1. A large yellow croaker antimicrobial peptide LcPLA2XIIA, characterized in that: The amino acid sequence is shown in SEQ ID NO.
1.
2. The encoding gene of the large yellow croaker antimicrobial peptide LcPLA2XIIA as claimed in claim 1, characterized in that: The nucleotide sequence is shown in SEQ ID NO.
2.
3. A preparation method of a large yellow croaker antimicrobial peptide LcPLA2XIIA, characterized in that: The steps include: (1) According to the mature peptide encoded by the ORF sequence of the antimicrobial peptide LcPLA2XIIA gene, primers were designed and the nucleic acid sequence corresponding to the mature peptide of LcPLA2XIIA was amplified by PCR, wherein the amino acid sequence of the mature peptide of the antimicrobial peptide LcPLA2XIIA is positions 19-186 of the amino acid sequence shown in SEQ ID NO.1; (2) Construction of recombinant expression vector pET32a / LcPLA2XIIA; (3) The recombinant expression vector in step (2) was transformed into host cells Rosetta DE3, the host cells were induced to express, and the antimicrobial peptide LcPLA2XIIA was obtained by affinity chromatography purification.
4. The preparation method of the antimicrobial peptide rLcPLA2XIIA according to claim 3, characterized in that: In the step (1), primers LcPLA2XIIAEF and primer The nucleotide sequence of primer LcPLA2XIIAEF is shown in SEQ ID NO.5, the nucleotide sequence of primer LcPLA2XIIAER is shown in SEQ ID NO.6, and the cDNA of LcPLA2XIIA is used as a template.
5. Use of the antimicrobial peptide LcPLA2XIIA prepared according to claim 3 or 4 in the preparation of antibacterial drugs, antifungal drugs or antiviral drugs.
6. The use according to claim 5, characterized in that: The fungi include Candida albicans.
7. The use according to claim 5, characterized in that: The pathogenic bacteria include Pseudomonas ayucidicatus, Aeromonas hydrophila, Vibrio parahaemolyticus, Escherichia coli or Staphylococcus aureus.
8. The use according to claim 5, characterized in that: The virus is infectious hematopoietic necrosis virus IHNV.
9. Use of the antimicrobial peptide LcPLA2XIIA prepared according to claim 3 or 4 in the preparation of an animal anti-pathogenic microorganism feed additive.
